Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Betta Pharmaceuticals Co., Ltd."
Count: 77
Selected: 0
NCT IDTitle
NCT03222622Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
NCT02801435Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
NCT05789602A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05007938Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
NCT04206072D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
NCT06041776Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06015568Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
NCT02959619Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
NCT03215693X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
NCT05433480A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
NCT05341583Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
NCT05869240BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
NCT05316259A Food-Effect Study of BPI-16350 in Healthy Subjects
NCT05843305A Study of BPI-452080 in Subjects With Solid Tumors
NCT05369312Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
NCT05341557A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT03791112A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor
NCT05341570A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668
NCT05329298A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
NCT05315180A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
NCT05302843A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
NCT02044328Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
NCT04930432Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT02478866Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
NCT02929290Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC
NCT02448797Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
NCT04946890A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT04464551The Absorption, Metabolism and Excretion of [14C]D-0316 in Human
NCT04415320X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
NCT03608007X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
NCT04058704A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
NCT03536481Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
NCT03510611A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
NCT02914990Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
NCT01855854Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
NCT01719536Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
NCT02726568High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
NCT03804541The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
NCT03188848Dose Escalating Study of BPI-3016 in Healthy Subjects
NCT03754530Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
NCT03749213Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
NCT03396185Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
NCT03349203Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
NCT02125240Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
NCT03346811Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
NCT02404675High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
NCT02574091Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
NCT01665417Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
NCT02544789Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
NCT01707329Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment